I feel like not much is known about the fact that Cellmid is cooking up a stake in the bone disorder market. (pun intended) We all know about the cancer, fibrotic and inflammatory, and ischemic heart disease pathways of research (Lyramid/Kinera).
But there is more. The bone disorder market is a huge one. The osteoporosis market alone is currently worth around US $9 billion.
https://www.prnewswire.com/news-rel...vartis-merck--co-inc-and-amgen-300454274.html
And Cellmid had a fairly recent patent application in that context. It certainly is more obvious to focus on something that is likely to see clinical trials soon. But do investors realise that IP exists for other important markets, too?
https://patentscope.wipo.int/search...cAn=AU2017050179&queryString=&maxRec=65223986
Anyway, I'm looking forward to 2018 and will likely make this my last post here this year. Happy Holidays everyone.
- Forums
- ASX - By Stock
- AN1
- Bone Disorders: A Huge Market
Bone Disorders: A Huge Market
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $336 | 42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1457234 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 340000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1457234 | 0.008 |
2 | 1111500 | 0.007 |
4 | 1006527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 340000 | 1 |
0.011 | 100000 | 1 |
0.012 | 100000 | 1 |
0.013 | 750000 | 1 |
0.015 | 440000 | 3 |
Last trade - 14.19pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
AN1 (ASX) Chart |